Psoriasis is a chronic inflammatory condition that typically presents with papulosquamous scaling dermatitis. While psoriasis' most visible effects are related to the skin, this condition involves inflammation at a more systemic level as well. Psoriasis is also associated with gut dysbiosis. This article reviews both dietary interventions and nutritional supplements that have been studied for their effects on psoriasis. This includes vitamin D, fish oil, antioxidants, curcumin, and probiotics. Many of these substances may impact psoriasis by modulating the microbiome or exerting anti-inflammatory effects.
Get full access to this article
View all access options for this article.
References
1.
KormanNJ.Management of psoriasis as a systemic disease: What is the evidence?. Br J Dermatol, 2020; 182:840.
2.
AlexisAF, BlackcloudP. Psoriasis in skin of color: epidemiology, genetics, clinical presentation, and treatment nuances. J Clin Aesthet Dermatol, 2014; 7:16.
3.
LangleyR., KruegerG, GriffithsC.Psoriasis: Epidemiology, clinical features, and quality of life. Ann Rheum Dis, 2005; 64(Suppl. 2):ii18–ii23.
4.
HuertaC, RiveroE, RodríguezLAG. Incidence and risk factors for psoriasis in the general population. Arch Dermatol, 2007; 143:1559–1565.
5.
KamiyaK, KishimotoM, SugaiJ, et al.Risk factors for the development of psoriasis. Int J Mol Sci, 2019; 20:4347.
6.
NaldiL.Risk factors for psoriasis. Curr Dermatol Rep, 2013; 2:58–65.
7.
SuomelaS, KainuK, OnkamoP, et al.Clinical associations of the risk alleles of HLA-Cw6 and CCHCR1*WWCC in psoriasis. Acta Derm Venereol, 2007; 87:127–134.
8.
MakRKH, HundhausenC, NestleFO. Progress in understanding the immunopathogenesis of psoriasis. Actas Dermosifiliogr, 2009; 100:2.
9.
GuojónssonJE, KárasonA, AntonsdóttirAA, et al.HLA-Cw6-positive and HLA-Cw6-negative patients with psoriasis vulgaris have distinct clinical features. J Invest Dermatol, 2002; 118:362–365.
10.
PușcașAD, CătanăA, PușcașC, et al.Psoriasis: Association of interleukin-17 gene polymorphisms with severity and response to treatment. Exp Ther Med, 2019; 18:875.
11.
ShaoS, GudjonssonJE. Epigenetics of psoriasis. Adv Exp Med Biol, 2020; 1253:209–221.
12.
BronckersIM, PallerAS, van GeelMJ, Van de KerkhofPC, SeygerM. Psoriasis in children and adolescents: Diagnosis, management and comorbidities. Paediatr Drugs, 2015; 17:373–384.
13.
GriffithsC, BarkerJ. Pathogenesis and clinical features of psoriasis. Lancet (London, England), 2007; 370:263–271.
14.
FarshchianM, AnsarA, SobhanM, et al.C-reactive protein serum level in patients with psoriasis before and after treatment with narrow-band ultraviolet B. An Bras Dermatol, 2016; 91:580.
15.
ScherJU, OgdieA, MerolaJF, et al.Preventing psoriatic arthritis: Focusing on patients with psoriasis at increased risk of transition. Nat Rev Rheumatol, 2019; 15:153–166.
16.
GarshickMS, TawilM, BarrettTJ, et al.Activated platelets induce endothelial cell inflammatory response in psoriasis via COX-1. Arterioscler Thromb Vasc Biol, 2020; 40:1340–1351.
17.
SikoraM, StecA, ChrabaszczM, et al.Gut microbiome in psoriasis: An updated review. Pathogens, 2020; 9:1–14.
18.
MyersB, BrownstoneN, ReddyV, et al.The gut microbiome in psoriasis and psoriatic arthritis. Best Pract Res Clin Rheumatol, 2019; 33:101494.
19.
ThioHB.The microbiome in psoriasis and psoriatic arthritis: The skin perspective. J Rheumatol Suppl, 2018; 94:30–31.
20.
SikoraM, ChrabąszczM, Waśkiel-BurnatA, et al.Claudin-3—A new intestinal integrity marker in patients with psoriasis: Association with disease severity. J Eur Acad Dermatol Venereol, 2019; 33:1907–1912.
21.
JensenP, SkovL. Psoriasis and obesity. Dermatology, 2016; 232:633–639.
22.
GuidaB, NapoleoneA, TrioR, et al.Energy-restricted, n-3 polyunsaturated fatty acids-rich diet improves the clinical response to immuno-modulating drugs in obese patients with plaque-type psoriasis: A randomized control clinical trial. Clin Nutr, 2014; 33:399–405.
23.
JensenP, ZachariaeC, ChristensenR, et al.Effect of weight loss on the severity of psoriasis: A randomized clinical study. JAMA Dermatology, 2013; 149:795–801.
24.
JensenP, ZachariaeC, ChristensenR, et al.Long-term effects of weight reduction on the severity of psoriasis in a cohort derived from a randomized trial: A prospective observational follow-up study. Am J Clin Nutr, 2016; 104:259–265.
25.
Del GiglioM, GisondiP, TessariG, GirolomoniG. Weight reduction alone may not be sufficient to maintain disease remission in obese patients with psoriasis: A randomized, investigator-blinded study. Dermatology, 2012; 224:31–37.
26.
Al-MutairiN, NourT. The effect of weight reduction on treatment outcomes in obese patients with psoriasis on biologic therapy: A randomized controlled prospective trial. Expert Opin Biol Ther, 2014; 14:749–756.
27.
GisondiP, Del GiglioM, Di FrancescoV, ZamboniM, GirolomoniG. Weight loss improves the response of obese patients with moderate-to-severe chronic plaque psoriasis to low-dose cyclosporine therapy: A randomized, controlled, investigator-blinded clinical trial. Am J Clin Nutr, 2008; 88:1242–1247.
28.
CastaldoG, RastrelliL, GaldoG, et al.Aggressive weight-loss program with a ketogenic induction phase for the treatment of chronic plaque psoriasis: A proof-of-concept, single-arm, open-label clinical trial. Nutrition, 2020; 74:110757.
29.
BhatiaBK, MillsopJW, DebbanehM, et al.Diet and psoriasis: Part 2. Celiac disease and role of a gluten-free diet. J Am Acad Dermatol, 2014; 71:350.
30.
AcharyaP, MathurM. Association between psoriasis and celiac disease: A systematic review and meta-analysis. J Am Acad Dermatol, 2020; 82:1376–1385.
31.
MichaëlssonG, GerdenB, HagforsenE, et al.Psoriasis patients with antibodies to gliadin can be improved by a gluten-free diet. Br J Dermatol, 2000; 142:44–51.
32.
MichaëlssonG, AhsS, HammarströmI, LundinI, HagforsenE. Gluten-free diet in psoriasis patients with antibodies to gliadin results in decreased expression of tissue transglutaminase and fewer Ki67+ cells in the dermis. Acta Derm Venereol, 2003; 83:425–429.
33.
HengMC.Phosphorylase kinase inhibition with curcumin in psoriasis. Cell Biol Res Ther, 2016; 2:5.
34.
HengM, SongM, HengM. Elevated phosphorylase kinase activity in psoriatic epidermis: Correlation with increased phosphorylation and psoriatic activity. Br J Dermatol, 1994; 130:298–306.
35.
BalasubramanianS, EckertR. Keratinocyte proliferation, differentiation, and apoptosis—differential mechanisms of regulation by curcumin, EGCG and apigenin. Toxicol Appl Pharmacol, 2007; 224:214–219.
36.
SunJ, ZhaoY, HuJ. Curcumin inhibits imiquimod-induced psoriasis-like inflammation by inhibiting IL-1beta and IL-6 production in mice. PLoS One, 2013; 8:e67078.
37.
AntigaE, BoncioliniV, VolpiW, et al.Oral curcumin (Meriva) is effective as an adjuvant treatment and is able to reduce IL-22 serum levels in patients with psoriasis vulgaris. Biomed Res Int, 2015; 2015:283634.
38.
BiliaA, BergonziM, IsacchiB, AntigaE, CaproniM. Curcumin nanoparticles potentiate therapeutic effectiveness of acitrein in moderate-to-severe psoriasis patients and control serum cholesterol levels. J Pharm Pharmacol, 2018; 70:919–928.
39.
PlutaR, JanuszewskiS, Ułamek-KoziołM. Mutual two-way interactions of curcumin and gut microbiota. Int J Mol Sci, 2020; 21:1055.
40.
GhoshSS, HeH, WangJ, et al.Curcumin-mediated regulation of intestinal barrier function: The mechanism underlying its beneficial effects. Tissue Barriers, 2018; 6:e1425085.
41.
UmarM, SastryKS, Al AliF, et al.Vitamin D and the pathophysiology of inflammatory skin diseases. Skin Pharmacol Physiol, 2018; 31:74–86.
42.
FiloniA, VestitaM, CongedoM, et al.Association between psoriasis and Vitamin D: Duration of disease correlates with decreased Vitamin D serum levels: An observational case-control study. Medicine (United States), 2018; 97:e11185.
43.
BarreaL, SavanelliMC, Somma CDi, et al.Vitamin D and its role in psoriasis: An overview of the dermatologist and nutritionist. Rev Endocr Metab Disord, 2017; 18:195.
44.
HamblyR, KirbyB. The relevance of serum vitamin D in psoriasis: A review. Arch Dermatol Res, 2017; 309:499–517.
45.
LeeY, SongG. Association between circulating 25-hydroxyvitamin D levels and psoriasis, and correlation with disease severity: A meta-analysis. Clin Exp Dermatol, 2018; 43:529–535.
46.
TheodoridisX, GrammatikopoulouM, StamouliF, et al.Effectiveness of oral vitamin D supplementation in lessening disease severity among patients with psoriasis: A systematic review and meta-analysis of randomized controlled trials. Nutrition, 2021; 82:111024.
47.
StanescuAMA, SimionescuAA, DiaconuCC. Oral vitamin D therapy in patients with psoriasis. Nutrients, 2021; 13:1–12.
48.
PardasaniAG, FeldmanS, ClarkAR. Treatment of psoriasis: An algorithm-based approach for primary care physicians. Am Fam Physician, 2000; 61:725–733.
49.
SoleymaniT, HungT, SoungJ. The role of vitamin D in psoriasis: A review. Int J Dermatol, 2015; 54:383–392.
50.
YamamotoEA, JørgensenTN. Relationships between vitamin D, gut microbiome, and systemic autoimmunity. Front Immunol, 2020; 10:3141.
51.
LiK, HuangT, ZhengJ, WuK, LiD. Effect of marine-derived n-3 polyunsaturated fatty acids on C-reactive protein, interleukin 6 and tumor necrosis factor α: A meta-analysis. PLoS One, 2014; 9:e88103.
52.
JiangJ, LiK, WangF, et al.Effect of marine-derived n-3 polyunsaturated fatty acids on major eicosanoids: A systematic review and meta-analysis from 18 randomized controlled trials. PLoS One, 2016; 11:e0147351.
53.
WójcikP, BiernackiM, WrońskiA, et al.Altered lipid metabolism in blood mononuclear cells of psoriatic patients indicates differential changes in psoriasis vulgaris and psoriatic arthritis. Int J Mol Sci, 2019; 20:4249.
54.
YangS, ChiC. Effects of fish oil supplement on psoriasis: A meta-analysis of randomized controlled trials. BMC Complement Altern Med, 2019; 19:354.
55.
ClarkC, TaghizadehM, NahavandiM, JafarnejadS. Efficacy of ω-3 supplementation in patients with psoriasis: A meta-analysis of randomized controlled trials. Clin Rheumatol, 2019; 38:977–988.
56.
ChenX, HongS, SunX, et al.Efficacy of fish oil and its components in the management of psoriasis: A systematic review of 18 randomized controlled trials. Nutr Rev, 2020; 78:827–840.
57.
JindalS, JindalN. Psoriasis and cardiovascular diseases: A literature review to determine the causal relationship. Cureus, 2018; 10:e2195.
58.
SiscovickD, BarringerT, FrettsA, et al.Omega-3 polyunsaturated fatty acid (fish oil) supplementation and the prevention of clinical cardiovascular disease: A science advisory from the American Heart Association. Circulation, 2017; 135:e867–e884.
59.
KharaevaZ, GostovaE, De LucaC, RaskovicD, KorkinaL. Clinical and biochemical effects of coenzyme Q(10), vitamin E, and selenium supplementation to psoriasis patients. Nutrition, 2009; 25:295–302.
60.
WangW-M, JinH-Z. Role of neutrophils in psoriasis. J Immunol Res, 2020; 2020:3709749.
61.
WaleckaI, OlszewskaM, RakowskaA, et al.Improvement of psoriasis after antibiotic therapy with cefuroxime axetil. J Eur Acad Dermatology Venereol, 2009; 23:957–958.
62.
YinG, LiJ, SunY, et al.[Fecal microbiota transplantation as a novel therapy for severe psoriasis]. Zhonghua Nei Ke Za Zhi, 2019; 58:782–785.
63.
GroegerD, O'MahonyL, MurphyEF, et al.Bifidobacterium infantis 35624 modulates host inflammatory processes beyond the gut. Gut Microbes, 2013; 4:325.
64.
Navarro-LópezV, Martínez-AndrésA, Ramírez-BoscàA, et al.Efficacy and safety of oral administration of a mixture of probiotic strains in patients with psoriasis: A randomized controlled clinical trial. Acta Derm Venereol, 2019; 99:1078–1084.
